Compare TRNS & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRNS | OMER |
|---|---|---|
| Founded | 1964 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 861.5M | 772.8M |
| IPO Year | 1995 | 2008 |
| Metric | TRNS | OMER |
|---|---|---|
| Price | $88.86 | $9.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $116.00 | $32.50 |
| AVG Volume (30 Days) | 178.4K | ★ 2.3M |
| Earning Date | 05-18-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | 0.57 | ★ 0.62 |
| Revenue | ★ $331,877,000.00 | $29,868,000.00 |
| Revenue This Year | $21.75 | N/A |
| Revenue Next Year | $7.55 | $233.22 |
| P/E Ratio | $156.19 | ★ $14.97 |
| Revenue Growth | ★ 19.20 | N/A |
| 52 Week Low | $50.23 | $3.34 |
| 52 Week High | $94.76 | $17.65 |
| Indicator | TRNS | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 51.54 | 40.66 |
| Support Level | $86.10 | $9.12 |
| Resistance Level | $94.48 | $11.88 |
| Average True Range (ATR) | 3.75 | 0.92 |
| MACD | -0.58 | 0.04 |
| Stochastic Oscillator | 28.98 | 62.40 |
Transcat Inc is a provider of accredited calibration, reliability, maintenance optimization, quality and compliance, validation, Computerized Maintenance Management System (CMMS), and pipette services. The Company is focused on providing services and products to high regulated industries, particularly the life sciences industry, which includes pharmaceutical, biotechnology, medical devices, and other FDA-regulated businesses, as well as aerospace and defense, and energy and utilities. It conducts business through two operating segments: Services and Distribution.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.